Inflammation‐associated remodelling and fibrosis in the lung – a process and an end point
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Fibrosis by common usage in the pathological and clinical literature is the end result of a healing process and synonymous with scarring. We would argue that its use to describe a dynamic series of events which may be reversible is unhelpful and that the term ‘lung remodelling’ is a better description for this process as it reflects changes in tissue organization that may or may not progress to ‘fibrosis’ as a final fixed point. Resolution, through reversal of active lung remodelling, by therapeutic intervention is possible providing the alveolar architecture remains intact. If the lung architecture is lost then healing by permanent fibrosis with loss of organ function is inevitable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver regeneration: from myth to mechanism
Taub, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1489 · Cited by 1,567 · cited 2×
“2003) and liver (Taub 2004) most tissues, including the lung, are not capable of organ regeneration and tissue damage leads to repair characterized by the formation of scar tissue (Kumar et al.”
BackgroundTime course of bleomycin‐induced lung fibrosis
Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W., & Breuer, R. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00220.x · Cited by 447
Chua, F., Gauldie, J., & Laurent, G. J. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0062tr · Cited by 305
Cited by
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Ojo, A. S., Balogun, S. A., Williams, O. T., & Ojo, O. S. (2020) · Pulmonary Medicine · doi:10.1155/2020/6175964 · Cited by 352
New Mechanisms of Pulmonary Fibrosis
Strieter, R. M., & Mehrad, B. (2009) · Chest · doi:10.1378/chest.09-0510 · Cited by 284
Nanoparticle-induced pulmonary toxicity
Li, J. J., Muralikrishnan, S., Ng, C.-T., Yung, L.-Y. L., & Bay, B.-H. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010021 · Cited by 254
cAMP and Epac in the regulation of tissue fibrosis
Insel, P. A., Murray, F., Yokoyama, U., Romano, S., Yun, H., Brown, L., Snead, A., Lu, D., & Aroonsakool, N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01847.x · Cited by 175
“Although certain types of tissue fibrosis can be reversed, it is generally irreversible, especially if its extent produces substantial loss of tissue parenchyma (Wallace et al., 2007; Marian, 2009; Ramachandran and Iredale, 2009; Chen and Frangogiannis, 2010; Dussaule et al., 2011).”
BackgroundMacrophage heterogeneity in respiratory diseases
Boorsma, C. E., Draijer, C., & Melgert, B. N. (2013) · Mediators of Inflammation · doi:10.1155/2013/769214 · Cited by 126
Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases
Sahu, I., Haque, A. K. M. A., Weidensee, B., Weinmann, P., & Kormann, M. S. D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.019 · Cited by 104
Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D. J., Seino, Y., & Yamada, Y. (2020) · Endocrinology · doi:10.1210/endocr/bqaa201 · Cited by 29
Yeh, J.-J., Lai, J.-N., Lin, C.-L., Hsu, C.-Y., & Kao, C.-H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047039 · Cited by 16
“15–19 An increase in interleukin 6 (IL-6) also promotes tumour formation.”
Metadata
- Authors
- Wallace, W. A. H., Fitch, P. M., Simpson, A. J., & Howie, S. E. M.
- Venue
- International Journal of Experimental Pathology
- Publisher
- Wiley
- Published
- 2006-12-20
- Volume
- 88
- Issue
- 2
- Pages
- 103-110
- ISSN
- 0959-9673 (ISSN-L)
- 1365-2613
- OpenAlex
- W2163110780
- Cited by
- 90
- References
- 3
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.